期刊文献+

外用5%米诺地尔酊联合二氧化碳点阵激光治疗斑秃的疗效观察 被引量:2

下载PDF
导出
摘要 目的 探讨外用5%米诺地尔酊联合二氧化碳点阵激光治疗斑秃(AA)的疗效及安全性.方法 选择AA患者90例,随机分为观察组和对照组各45例.观察组采用外用5%米诺地尔酊联合二氧化碳点阵激光治疗,对照组采用外用5%米诺地尔酊治疗.疗程4个月,随访6个月.比较两组有效率、治愈率、不良反应及复发率.结果 两组患者治疗4个月后,观察组有效率91.0%,治愈率60.0%,对照组有效率73.0%,治愈率55.6%.两组有效率比较差异有统计学意义(P<0.05).至随访结束,观察组复发率2.22%,对照组复发率17.78%.两组复发率比较差异有统计学意义(P<0.05).两组患者均未出现明显不良反应.结论 外用5%米诺地尔酊联合点阵激光治疗AA可以提高疗效,不良反应少,疗效较为持续,值得推广. ObjectiveTo investigate the clinical eficacy and safety profile of topical 5%minoxidil solution combined with fractional carbon dioxide laser in treating alopecia areata(AA).Methods 90 patients with alopecia areata were randomly allocated into 2 groups:45 cases in the trial group treated with topical 5%minoxidil solution combined with fractional carbon dioxide laser and 45 cases in the control group treated with topical 5%minoxidil solution.The efficacy,adverse reactions and short-term recurrence rate were observed after 4 months of treatment and 6 months follow-up.ResultsAfter 4 months of the treatment,the total effective rate and the curative rate in the trial group were 91.0%and 60.0%,respectively,while the effective rate and the curative rate in the control group were 73.0%and 55.6%respectively.There was a significant dference in effective rate between the trial group and the control group(P<0.05).After 6 months follow-up,the recurrence rates in the trial group and control group were 2.27%and 18.60%,respectively(P<0.05 between the two groups).No serious side-effects were observed in either group during the treatment.Conclusion Topical 5%minoxidil solution combined with fractional carbon dioxide laser is a safe and effective treatment for alopecia areata.It is worthy of clinical application and promotion.
出处 《浙江临床医学》 2023年第2期257-258,261,共3页 Zhejiang Clinical Medical Journal
基金 浙江省医药卫生科技项目(2019RC289) 嘉兴市2019-2021年周期中医药重点学科建设计划项目(2019XK-C06)。
关键词 斑秃 米诺地尔 点阵激光 Alopecia areata Minoxidil Fractional carbon dioxide laser
  • 相关文献

参考文献2

二级参考文献13

  • 1Seetharam KA. A|opecia areata: an update[J]. Indian J Dermatol Venereol Leprol, 2013, 79(5): 563-575.
  • 2Tosti A, Piraccini BM, Pazzaglia M, et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/uni- versalis[J]. J Am Acad Dermatol, 2003, 49(1): 96-98.
  • 3Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluoci- nolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing local- ized acneform response[J]. Dermatologica, 1970, 141(3): 193-202.
  • 4Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists" guidelines for the management of alopecia areata 2012[J]. Br J Dermatol, 2012, 166(5): 916-926.
  • 5Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata in- vestigational assessment guidelines-Part II. National Alopecia Areata Foundation[J]. J Am Acad Dermatol, 2004, 51(3): 440-447.
  • 6Charuwichitratana S, Wattanakrai P, Tanrattanakorn S. Random- ized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream[J]. Arch Der- matol, 2000, 136(10): 1276-1277.
  • 7Price VH. Alopecia areata: clinical aspects[J]. J Invest Dermatol, 1991, 96(5): 68S.
  • 8Madani S, Shapiro J. Alopecia areata update [J]. J Am Acad :' Dermatol, 2000, 42(4): 549-566, 567-570.
  • 9Finner AM. Alopecia areata: clinical presentation, diagnosis, and unusual cases[J]. Dermatol Ther, 2011, 24(3): 348-354.
  • 10Alkhalifah A. Alopecia areata update[J]. Dermatol Clin, 2013, 31 (1): 93-108.

共引文献40

同被引文献20

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部